Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer

Bevacizumab in neoadjuvant therapy provides a new hope of improved survival for patients with triple-negative breast cancer (TNBC) by targeting vascular endothelial growth factor in combination with chemotherapy, but curative effect is limited by bevacizumab’s continuous use while mechanisms remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu, Ji, Xuemei, Kang, Nannan, Zhou, Junfei, Liang, Xue, Li, Jiaxin, Han, Tianzhen, Zhao, Chen, Yang, Tianwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678839/
https://www.ncbi.nlm.nih.gov/pubmed/33214550
http://dx.doi.org/10.1038/s41419-020-03161-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678839/
https://www.ncbi.nlm.nih.gov/pubmed/33214550
http://dx.doi.org/10.1038/s41419-020-03161-x

Ejemplares similares